Literature DB >> 11564780

CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1.

M Martin1, X Romero, M A de la Fuente, V Tovar, N Zapater, E Esplugues, P Pizcueta, J Bosch, P Engel.   

Abstract

CD84 is a member of the CD2 subset of the Ig superfamily of cell surface molecules. Its cytoplasmic tail binds to Src homology 2 domain-containing protein 1A (signaling lymphocytic activation molecule-associated protein), a protein encoded by the X-linked lymphoproliferative disease gene. It is preferentially expressed on B lymphocytes, monocytes, and platelets. We show that it is also expressed on thymocytes and T cells. CD84 was positive on CD4-CD8- thymocytes, and its expression decreased with cell maturation. It is expressed on mature T cells preferentially on CD45RO+. To identify the CD84 ligand, we generated a soluble Ig fusion protein containing the human CD84 extracellular domains (CD84-Ig). Because receptor-ligand interactions occur between several members of this subfamily, we assayed CD84-Ig binding with all members of the CD2 family. CD84-Ig bound to CD84-transfected cells, whereas no binding was detected with cells expressing other CD2 subfamily receptors, showing that CD84 binds to itself. Anti-CD84 mAbs recognizing epitopes wholly within domain 1 of CD84 blocked the binding of the CD84-Ig fusion protein to CD84-transfected cells and platelets. Data from CD84 domain human/mouse chimeras further revealed that only the first extracellular domain of the molecule is involved in the ligand receptor recognition. The CD84-CD84 interaction was independent of its cytoplasmic tail. Finally, concurrent ligation of human CD84 with mAbs or CD84-Ig and CD3 enhanced IFN-gamma secretion in human lymphocytes. Thus, CD84 is its own ligand and acts as a costimulatory molecule.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564780     DOI: 10.4049/jimmunol.167.7.3668

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  CD84 negatively regulates IgE high-affinity receptor signaling in human mast cells.

Authors:  Damiana Álvarez-Errico; Irene Oliver-Vila; Erola Ainsua-Enrich; Alasdair M Gilfillan; César Picado; Joan Sayós; Margarita Martín
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

Review 2.  Minding the gaps to promote thrombus growth and stability.

Authors:  Lawrence F Brass; Li Zhu; Timothy J Stalker
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Large-scale screening for novel low-affinity extracellular protein interactions.

Authors:  K Mark Bushell; Christian Söllner; Benjamin Schuster-Boeckler; Alex Bateman; Gavin J Wright
Journal:  Genome Res       Date:  2008-02-22       Impact factor: 9.043

Review 4.  Sequence, structure, function, immunity: structural genomics of costimulation.

Authors:  Kausik Chattopadhyay; Eszter Lazar-Molnar; Qingrong Yan; Rotem Rubinstein; Chenyang Zhan; Vladimir Vigdorovich; Udupi A Ramagopal; Jeffrey Bonanno; Stanley G Nathenson; Steven C Almo
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  CD84 is a survival receptor for CLL cells.

Authors:  I Binsky-Ehrenreich; A Marom; M C Sobotta; L Shvidel; A Berrebi; I Hazan-Halevy; S Kay; A Aloshin; I Sagi; D M Goldenberg; L Leng; R Bucala; Y Herishanu; M Haran; I Shachar
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

6.  CD84 mediates CLL-microenvironment interactions.

Authors:  A Marom; A F Barak; M P Kramer; H Lewinsky; I Binsky-Ehrenreich; S Cohen; A Tsitsou-Kampeli; V Kalchenko; Y Kuznetsov; V Mirkin; N Dezorella; M Shapiro; P L Schwartzberg; Y Cohen; L Shvidel; M Haran; S Becker-Herman; Y Herishanu; I Shachar
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

7.  Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro.

Authors:  Shan Feng; Suzi H Madsen; Natasja N Viller; Anita V Neutzsky-Wulff; Carsten Geisler; Lars Karlsson; Kalle Söderström
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397

8.  Characterization of Ly108 in the thymus: evidence for distinct properties of a novel form of Ly108.

Authors:  Mala Dutta; Pamela L Schwartzberg
Journal:  J Immunol       Date:  2012-03-05       Impact factor: 5.422

9.  Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions.

Authors:  Kyung-Mi Lee; John P Forman; Megan E McNerney; Susan Stepp; Sumalatha Kuppireddi; Dustin Guzior; Yvette E Latchman; Mohamed H Sayegh; Hideo Yagita; Chul-Kyu Park; Seog Bae Oh; Christoph Wülfing; John Schatzle; Porunelloor A Mathew; Arlene H Sharpe; Vinay Kumar
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

10.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.